PEA (palmitoylethanolamide).
Endocannabinoid support without the high. Pain and inflammation. A fat-like molecule your own cells build on demand under stress. Taken daily, it's studied for everyday nerve and joint comfort, acting through a nuclear receptor rather than cannabinoid receptors.
Reviewed March 2026
- Category
- Compound
- Also filed under
- PainInflammationNeuroprotection
What PEA (Palmitoylethanolamide) is, and what it does.
- Does it work
- Good. Over 600 studies. Used in Europe for decades.
- How much to take
- Start at 300mg a day and settle in the 300 to 600mg band, often split across two servings. The 1,200mg seen in trials is a research condition, not a daily target.
- Time to feel it
- Give it two to four weeks of daily use. Most of the change people report lands between weeks four and eight.
- The first dose
- Day one is quiet. It works through a nuclear receptor and an enzyme it competes for, so the first dose does its work without registering as a sensation.
- With regular use
- 2-4 weeks minimum. Full benefit at 8 weeks.
- How well tolerated
- Well tolerated. No known drug interactions. Non-addictive.
- How it feels
- Gradual pain reduction over weeks. Not instant.
- The overlooked benefit
- It competes with anandamide for the same breakdown enzyme, so it raises your own endocannabinoid tone indirectly rather than binding those receptors itself.
300 to 600mg a day is where PEA (Palmitoylethanolamide) works.
Source: Petrosino & Di Marzo 2017 review; Paladini et al. 2016 meta-analysis (12 RCTs, n=1,188).
The proof, claim by claim.
What these words mean
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
PEA (Palmitoylethanolamide) has solid evidence, with 10 cited human studies on this page.
- persistent nerve and muscle discomfortMeta-analysis
- a healthy inflammatory responseAnimal study
2 more claims
- PPAR-alpha receptor activationIn vitro study
- absorption from reduced particle size preparationsRandomised trial
Questions people ask about PEA (Palmitoylethanolamide).
- When should I take it?
- Timing matters less than consistency. Pick a time that works for you and take it daily.
2 more questions
- Can I take it with other supplements?
- Usually fine. The main thing to watch is not doubling up on the same ingredient from different products. If you're on prescription meds, check with your pharmacist first.
- Any side effects to watch for?
- Most people tolerate it well at recommended doses. GI upset is the most common complaint with any supplement. Start with a lower dose and work up. If something feels off, stop and reassess.
Why these belong in the same formula, 15 pairings
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Luteolin acts on mast cell and glial activation while PEA acts largely through PPAR-alpha, and the co-ultramicronised PEA plus luteolin combination has been a defined pharmaceutical-grade preparation for years.
PEA and OEA are both N-acylethanolamines released from membrane NAPE by the same phospholipase D and cleared by the same FAAH and NAAA hydrolases. Supplying one raises competition for those hydrolases and slows breakdown of the other.
Cannabidiol interferes with fatty acid amide hydrolase activity and with the fatty-acid-binding proteins that shuttle acylethanolamines to it. Slowing that route leaves endogenous and supplemented PEA available for longer.
Quercetin, like luteolin, dampens mast cell mediator release, an arm PEA also touches through its action on those cells. The pairing follows the same logic as the established luteolin combination.
Palmitoylethanolamide is a lipophilic fatty acid amide with very low water solubility, so how much reaches the circulation depends heavily on the vehicle. A phospholipid-based delivery system was reported to increase its solubility and systemic exposure. The phospholipid does the dispersing work. It does not change what the molecule does once absorbed.
Lecithin is the everyday source of the phosphatidylcholine used to build dispersions of lipophilic actives. In a palmitoylethanolamide product it forms mixed micelles that keep the amide in a dispersible state through the gut. Sunflower lecithin is chosen where a soy-free label is wanted. The physical chemistry is the same.
Palmitoylethanolamide dissolves in fat and not in water, so a lipid carrier and a fat-containing meal both help it disperse for absorption. Medium-chain triglycerides are used as the carrier because they stay liquid and resist oxidation. The size of the exposure difference for this specific pairing has not been quantified.
Palmitoylethanolamide belongs to the N-acylethanolamine family, whose members are released from membrane N-acyl-phosphatidylethanolamines and broken down by fatty acid amide hydrolase. Dietary long-chain omega-3 fatty acids feed the same membrane pool and give rise to their own ethanolamides. The two therefore compete for and share the same enzymes, which is a mechanistic relationship rather than a measured combination effect.
A combination product containing palmitoylethanolamide alongside alpha-lipoic acid and other antioxidants was assessed in adults with high blood sugar and nerve-related symptoms. Because the product was fixed, the contribution of any single component cannot be separated out. The pairing has been studied together, which is more than most combinations can claim, but the attribution stays open.
Superoxide dismutase appeared in the same fixed combination with palmitoylethanolamide in a randomised evaluation. The two act on different systems, an antioxidant enzyme and a nuclear receptor ligand, and were only ever given together. Read the result as belonging to the product, not to either ingredient.
A multiple baseline study looked at probiotics and palmitoylethanolamide as individual interventions in people with joint discomfort. That design tracks each participant across phases rather than randomising between groups, so it is suggestive rather than confirmatory. It is one of the few places the two have been examined in the same protocol.
A retrospective review reported changes in discomfort measures and sudomotor function in adults with high blood sugar who used a palmitoylethanolamide and baicalin supplement. Retrospective data show association, not cause, and there was no randomised comparison. The pairing is a commercial fixed combination.
Palmitoylethanolamide and curcumin appear together in joint comfort formulas, both as lipophilic actives that need a dispersion system. They act through different targets and have not been tested against each other in a controlled comparison. The pairing is commercial practice with a plausible mechanistic story behind it.
Boswellia resin extracts are combined with palmitoylethanolamide in products aimed at joint comfort and mobility. Their mechanisms are separate, and no controlled study has isolated what each contributes in the blend. Read the pairing as formulation practice.
Palmitoylethanolamide is usually delivered in an oil or phospholipid matrix that can oxidise over shelf life. Mixed tocopherols are the standard antioxidant added to such matrices. The role is protective for the product. It does not alter the amide's activity in the body.
Nothing specific on file for PEA (Palmitoylethanolamide). Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What PEA (Palmitoylethanolamide) actually does.
Palmitoylethanolamide is a molecule your body makes on demand from cell membrane material rather than storing it ahead of time.
3 more mechanisms
Two different enzymes break it down, one of which also breaks down a related signaling molecule called anandamide.
It activates a receptor inside the cell nucleus, and lab studies where that receptor is missing show many of its measured effects disappear. It has little direct effect on the classic cannabinoid receptors.
It occurs naturally in some foods like egg yolk, peanuts and soy, and the body makes low levels of it that rise locally when cells are under stress.
Where PEA (Palmitoylethanolamide) comes from.
The molecule is put together from two simple parts: a fatty acid that usually comes from a plant oil, and a small amine. Foods like egg yolk and peanuts contain it naturally, but in amounts far too small to collect, so it is made in a reactor instead. After it is made and cleaned up, the last step is either grinding it very fine or mixing it into a fat carrier, because it does not dissolve in water on its own.
What this route gives you
The same molecule is reached more than one way. Which route a given product used is a manufacturing choice, and the finished compound is the same either way.
5 steps on record
Palmitic acid is obtained from vegetable oil sources such as palm or coconut by hydrolysis and fractionation. Ethanolamine is an industrial amine made from ethylene oxide and ammonia.
The fatty acid and the amine are condensed to the amide, either by direct thermal amidation, through an activated acyl intermediate, or enzymatically with an immobilised lipase in a solvent system.
The crude amide is recrystallised from solvent and washed to remove unreacted acid, free ethanolamine and diacylated by-products.
Purity is set by chromatography against a reference standard, with residual solvent, free fatty acid and heavy metal limits recorded on the certificate of analysis.
The dried crystals are either jet milled to a stated particle size distribution or built into a phospholipid or surfactant dispersion, then encapsulated or sachet filled.
Getting PEA (Palmitoylethanolamide) from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
1 more form
The essence, in one line each.
- In a meta-analysis of trials in 742 adults with long-standing pain, taking micron-size palmitoylethanolamide for 60 days was linked to a greater reduction in pain scores than taking it for 30 days.Meta-analysis, in patients with chronic pain. Schweiger et al., 2024 (Nutrients). PMID 38892586 ↗
13 more findings
- In a crossover trial, palmitoylethanolamide lowered acute menstrual pain scores compared with placebo.Randomised trial. Rao et al., 2025 (Women & Health). PMID 39910730 ↗
- In healthy men, palmitoylethanolamide did not show a detectable effect on recovery from exercise-induced muscle damage. The trial failed to detect a difference rather than showing none exists.Randomised trial. Schouten et al., 2024 (Medicine and Science in Sports and Exercise). PMID 39086058 ↗
- In a 6-week randomised crossover trial in young, healthy adults, a formulated palmitoylethanolamide supplement significantly increased blood levels of the marker BDNF and improved memory by reducing errors on a learning test, compared to a placebo.Randomised crossover trial. Kim N et al., 2024 (Nutrients). PMID 38398813 ↗
- A preliminary meta-analysis of three studies confirmed that palmitoylethanolamide supplementation reduces cognitive impairment in adults with diagnosed neurocognitive conditions.Meta-analysis, in people with neurocognitive disorders. Colizzi M et al., 2022 (Frontiers in Psychiatry). PMID 36387000 ↗
- A systematic review of clinical and preclinical work questioned whether the available data support a role for palmitoylethanolamide in this area, finding the evidence thin.Systematic review. Bortoletto R et al., 2023 (Frontiers in Psychiatry). PMID 37533892 ↗
- In a randomised trial of 120 adults with diagnosed long-term nerve-related low back pain, a phospholipid-based form of palmitoylethanolamide taken for 8 weeks significantly improved pain, disability, sleep, and quality of life compared to a placebo.Randomised trial, in adults with neuropathic LBP. Khan A et al., 2026 (Biomedicines). PMID 41751279 ↗
- Palmitoylethanolamide, taken in a combination with Acmella oleracea extract for 4 weeks, was associated with improved daily functioning in an open-label trial in 60 adults with a diagnosed nerve-related back condition.Open-label trial, in subjects with low back pain with sciatica. Raju HN et al., 2026 (Cureus). PMID 42255791 ↗
- In a small 11-week trial in four adults with a diagnosed joint condition, taking probiotics plus palmitoylethanolamide was linked to improved function and wellbeing for all participants, and a clear reduction in pain for one of them.Randomised trial, in individuals with osteoarthritis. Taye I et al., 2026 (BMC Complementary Medicine and Therapies). PMID 41709243 ↗
- A palmitoylethanolamide and Equisetum arvense supplement was evaluated clinically, with results reported for the combination as a whole.Open-label trial. Invernizzi M et al., 2025 (Medical Sciences). PMID 40981167 ↗
- In a 6-month retrospective study of adults with a diagnosed blood-sugar condition and related nerve discomfort, a supplement containing palmitoylethanolamide and baicalin was associated with a significant reduction in pain, while no change was seen in untreated adults.Cohort study, in type 2 diabetes mellitus patients with clinically diagnosed diabetic peripheral neuropathy. Scibetta S et al., 2026 (Nutrients). PMID 42356281 ↗
- In a retrospective study of 61 women with a diagnosed head pain condition, taking a supplement with phycocyanin and palmitoylethanolamide around their period for 3 months was associated with reduced severity, duration, and number of head pain days during that time.Cohort study, in women diagnosed with migraine without aura. Allais G et al., 2026 (Biomedicines). PMID 42072406 ↗
- A palmitoylethanolamide preparation was associated with reduced joint discomfort measures in dogs and cats. A veterinary finding that does not transfer to people.Animal study. Briskey D et al., 2026 (Frontiers in Veterinary Science). PMID 41767672 ↗
- A single case description with a mechanistic rationale for palmitoylethanolamide in restless leg symptoms. A case report describes one person and establishes nothing about frequency or cause.Case report, in a gabapentin-treated patient with restless legs syndrome. Bugnicourt JM et al., 2026 (Neurological Sciences). PMID 41504926 ↗
Chosen from the 448 we read for PEA (Palmitoylethanolamide).
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.